Oxygen Of The Saccharide Radical Bonded Directly To A Polycyclo Ring System Of Three Or More Carbocyclic Rings Patents (Class 514/33)
  • Patent number: 10493028
    Abstract: The invention relates to stable vancomycin hydrochloride powder for oral liquid formulations. Also provided herein are methods of using vancomycin oral liquid formulations for the treatment of certain diseases such as Clostridium difficile pseudomembranous colitis and Staphylococcal enterocolitis as well as kits and related products thereof.
    Type: Grant
    Filed: October 24, 2017
    Date of Patent: December 3, 2019
    Assignee: CutisPharma, Inc.
    Inventors: Indu Muni, Peter Mione, Anisa Gandhi, Cristina LeChiara
  • Patent number: 10450340
    Abstract: 2-pyrrolino-13-deoxyanthracycline derivatives, medical uses thereof, and a process for making them. A 2-pyrrolino-13-deoxyanthracycline and a 13-deoxyanthracycline can be administered to a patient simultaneously or sequentially in amounts to produce a synergistic therapeutic effect with increased potency and efficacy, compared to the sum of the effects of each drug when administered alone. A composition or preparation of a 2-pyrrolino-13-deoxyanthracycline and a 13-deoxyanthracycline for producing a potent anticancer therapeutic effect is also provided.
    Type: Grant
    Filed: February 16, 2017
    Date of Patent: October 22, 2019
    Assignee: MONOPAR THERAPEUTICS INC.
    Inventors: Richard Olson, Gerald Walsh
  • Patent number: 10188689
    Abstract: The invention disclosed herein relates to the use of an extract of Dodonaea viscosa in breast cancer therapy, either alone or in combination with other breast cancer therapies.
    Type: Grant
    Filed: September 25, 2015
    Date of Patent: January 29, 2019
    Assignee: STELLENBOSCH UNIVERSITY
    Inventors: Nokwanda Pearl Makunga, Anna-Mart Engelbrecht
  • Patent number: 10039704
    Abstract: A composition that is useful in a skin function improving agent includes at least a sapogenol, and a collagen hydrolysate. This composition can be used in a skin function improving agent and is particularly useful in a skin function improving agent for inhibiting transdermal moisture loss and/or for retaining the moisture in the stratum corneum.
    Type: Grant
    Filed: October 4, 2016
    Date of Patent: August 7, 2018
    Assignee: J-OIL MILLS, INC.
    Inventors: Shuichi Kamo, Toshiro Sato, Rumi Kawahara, Shunsuke Suzuki
  • Patent number: 9974799
    Abstract: This invention provides compositions, methods and process of producing extracts from Xanthoceras sorbifolia. The extract comprises alkaloids, coumarins, saccharides, proteins, polysaccharides, glycosides, saponins, tannins, acid, flavonoids and others. The composition can be used for treating cancer, arthritis, rheumatism, poor circulation, arteriosclerosis, Raynaud's syndrome, angina pectoris, cardiac disorder, coronary heart disease, headache, dizziness, kidney disorder, impotence and premature ejaculation; for preventing cerebral aging; for improving memory, cerebral functions; or for curing enuresis, frequent micturition, urinary incontinence, dementia, weak intelligence and Alzheimer's disease, autism, brain trauma, Parkinson's disease or other diseases caused by cerebral dysfunctions, and treating arthritis, rheumatism, poor circulation, arteriosclerosis, Raynaud's syndrome, angina pectoris, cardiac disorder, coronary heart disease, headache, dizziness, kidney disorder.
    Type: Grant
    Filed: October 29, 2015
    Date of Patent: May 22, 2018
    Assignee: Pacific Arrow Limited
    Inventors: Pui-Kwong Chan, May Sung Mak, Yun Wang
  • Patent number: 9884884
    Abstract: This invention relates to the compound extracted from husk and fruit stem of Xanthoceras Sobifolia and its extracting method and use thereof.
    Type: Grant
    Filed: July 5, 2005
    Date of Patent: February 6, 2018
    Inventors: Baizhen Yang, Songjian Wang, Congfu Zhao
  • Patent number: 9782409
    Abstract: Disclosed herein are compositions comprising lopinavir alone or in combination with ritonavir for use as a medicament in the treatment of cancer or benign proliferative disorders (warts) or in the prevention of the development of cancer. Pharmaceutical compositions formulated for topical application comprising a therapeutically effective amount of lopinavir or a therapeutically effective amount lopinavir and ritonavir in a pharmaceutically acceptable vehicle are also provided. Also disclosed are methods of treating a patient having an HPV related dysplasia of the cervix comprising administering to said patient a therapeutically effective dose of the disclosed pharmaceutical compositions.
    Type: Grant
    Filed: October 23, 2014
    Date of Patent: October 10, 2017
    Assignee: The University of Manchester
    Inventors: Ian Hampson, Lynne Hampson
  • Patent number: 9724329
    Abstract: Methods of treatment or prevention of a cancerous or pre-cancerous condition, of slowing or preventing growth of a cancerous condition, of stimulating a cell-mediated immune response, stimulating a Th1 helper T cell response against a pathogen in a mammal and of treating or preventing inflammatory diseases or disorders that involve administration of N-methyl pyrrolidone (NMP) or a physiologically acceptable salt, solvate, tautomer or prodrug thereof are provided. Also provided are formulations of an active agent.
    Type: Grant
    Filed: June 21, 2011
    Date of Patent: August 8, 2017
    Assignee: Peter MacCallum Cancer Institute
    Inventors: Andy Kang-Wei Hsu, Jake Shortt, Paul Neeson, Ricky Wayne Johnstone, David Ritchie
  • Patent number: 9624237
    Abstract: The present invention relates to an oridonin functionalized selenium nanoparticle, method of preparing and use thereof for anti-cancer and anti-inflammatory treatments. The present invention provides oridonin functionalized selenium nanoparticle that is stable, water soluble and storable.
    Type: Grant
    Filed: June 19, 2015
    Date of Patent: April 18, 2017
    Assignee: Macau University of Science and Technology
    Inventors: Jiang Pi, Jiye Cai, Hua Jin
  • Patent number: 9585820
    Abstract: The invention relates generally to formulations having one or more ingredients segregated from other constituents of the same formulation. The formulations are typically for topical application to an integument.
    Type: Grant
    Filed: May 20, 2014
    Date of Patent: March 7, 2017
    Assignee: Avon Products, Inc.
    Inventors: Michael A. Lull, Ashley L. Howell, Candice DeLeo Novack
  • Patent number: 9416151
    Abstract: The present invention pertains to novel uses of glycyrrhetinic acid (GA), glycyrrhizic acid (GLA) and related compounds for prevention and/or treatment of pulmonary fibrosis, in particular, irradiation-induced pulmonary fibrosis. Also embodied are therapeutic uses of prodrugs, metabolites, derivatives (e.g., acids, esters and ethers), and salts of glycyrrhetinic acid (GA) and glycyrrhizic acid (GLA). The present invention also provides for therapeutic or pharmaceutical compositions comprising a compound of the invention in a form that can be combined with a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: August 25, 2010
    Date of Patent: August 16, 2016
    Inventors: Lurong Zhang, Weijian Zhang, Jianhua Xu, Shanmin Yang
  • Patent number: 9393190
    Abstract: The invention relates to the use of an oral composition comprising steviol, a steviol precursors or Stevia extract as skin tanning agent. It further relates methods of enhancing the natural skin tan by oral administration of an effective amount of Steviol, a Steviol precursor or Stevia extract.
    Type: Grant
    Filed: March 1, 2011
    Date of Patent: July 19, 2016
    Assignee: DSM IP ASSETS B.V.
    Inventors: Regina Goralczyk, Remo Graeub
  • Patent number: 9168268
    Abstract: SAPONINS AND CHROMANS DERIVATIVES MIXTURE COMPOSITIONS AGAINST LEISHMANIASIS, TRYPANOSOMIASIS AMERICANA, MALARIA, TRYPANOSOMIASIS AFRICANA AND FASCIOLA HEPATICA, is a composition of saponins and chromans derivatives. The saponins are triterpene types and chromans are hydrazones derivatives. This composition is a therapeutic agent against tropical diseases.
    Type: Grant
    Filed: April 9, 2013
    Date of Patent: October 27, 2015
    Assignee: Universidad de Antioquia
    Inventors: Luis Fernando Echeverri-Lopez, Winston Quinones-Fletcher, Luis Fernando Torres-Roldan, Rosendo Ricardo Archbold-Joseph, Gustavo Adolfo Escobar-Pelaez, Sara Maria Robledo-Restrepo, Ivan Dario Velez-Bernal, Diana Lorena Munoz-Herrera, Adriana Maria Restrepo-Agudelo, Juan Alejandro Daza-Figueredo, Sergio Andres Pulido-Munoz, Edwin Andres Correa-Garces
  • Publication number: 20150141358
    Abstract: The present invention relates to reduced toxicity of functional alcoholic beverage composition comprising distilled alcohol, deionized water, 18?-Glycyrrhizin or 18?-Glycyrrhizin and a sugar alcohol or sugars, having pH in the range of 4.0-9.0. More particularly, alcoholic beverage composition comprises distilled alcohol, deionized water, 18?-Glycyrrhizin or 18?-Glycyrrhizin and a sugar alcohol/sugars as hepato-protectants. The present invention provides an alcoholic beverage for reducing hepatotoxicity caused by its consumption and a process to manufacture the said alcoholic beverage.
    Type: Application
    Filed: April 28, 2014
    Publication date: May 21, 2015
    Applicant: CHIGURUPATI TECHNOLOGIES PRIVATE LIMITED
    Inventors: Harsha Chigurupati, Manish Radheshyam Biyani, Biswajit Auddy
  • Publication number: 20150050319
    Abstract: The present disclosure encompasses QS-21-based structurally-defined adjuvants to address the need for stronger, safer, and easier-to-access adjuvants. The new compositions can provide tools for addressing long-standing mechanistic questions concerning saponin immune-potentiation through structure-activity-relationship (SAR) studies. Most advantageously, the compounds of the disclosure may be formulated into pharmaceutically acceptable compositions, including vaccines that may be delivered to a subject human or animal subject. The compounds can then act as, for example, an adjuvant to augment an immunological response to a vaccine immunogen.
    Type: Application
    Filed: March 12, 2013
    Publication date: February 19, 2015
    Applicant: THE UAB RESEARCH FOUNDATION
    Inventor: Pengfei Wang
  • Publication number: 20150017099
    Abstract: The invention provides methods and compositions for the diagnosis, prognosis and treatment of respiratory tract diseases. Specifically, the invention provides diagnosis, prognosis and treatment of respiratory infections using bitter and sweet taste signal transduction pathways. In one aspect, the invention relates to a method for treating a respiratory infection by administering a composition to the respiratory tract of a subject in an amount capable of activating bitter taste signaling and/or inhibiting sweet taste signaling. The composition comprises at least a bitter receptor agonist and, optionally, a pharmaceutically acceptable carrier for delivering the composition to the respiratory tract. In another aspect, the invention relates to a composition for treatment of a respiratory infection. Such composition comprises at least a bitter receptor agonist and, optionally, a pharmaceutically acceptable carrier for delivering the composition to the respiratory tract.
    Type: Application
    Filed: January 25, 2013
    Publication date: January 15, 2015
    Inventors: Noam A. Cohen, Robert J. Lee, Danielle R. Reed
  • Patent number: 8900589
    Abstract: The present invention relates to conjugates of therapeutically useful anthracyclines with carriers such as polyclonal and monoclonal antibodies, proteins or peptides of natural or synthetic origin; methods for their preparation, pharmaceutical composition containing them and use thereof in treating certain mammalian tumors.
    Type: Grant
    Filed: July 14, 2009
    Date of Patent: December 2, 2014
    Assignee: Genetech, Inc.
    Inventors: Italo Beria, Michele Caruso, John A. Flygare, Vittoria Lupi, Rita Perego, Paul Polakis, Andrew Polson, Matteo Salsa, Susan D. Spencer, Barbara Valsasina, Robert L. Cohen
  • Patent number: 8889842
    Abstract: The present invention relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, intermediates thereto, and uses thereof. QS-7 is a potent immuno-adjuvant that is significantly less toxic than QS-21, a related saponin that is currently the favored adjuvant in anticancer and antiviral vaccines. Tedious isolation and purification protocols have hindered the clinical development of QS-7. A novel semi-synthetic method is provided wherein a hydrolyzed prosapogenin mixture is used to synthesize QS-7, QS-21, and related analogs, greatly facilitating access to QS-7 and QS-21 analogs for preclinical and clinical evaluation.
    Type: Grant
    Filed: September 13, 2012
    Date of Patent: November 18, 2014
    Assignee: Sloan-Kettering Insititute for Cancer Research
    Inventors: David Y. Gin, Michelle Adams, Kai Deng, Nicholas Perl, Annie Won, Philip Livingston, Govind Ragupathi
  • Publication number: 20140323420
    Abstract: Described herein are compositions and methods for treating or preventing a sexually transmitted infection in a subject
    Type: Application
    Filed: November 8, 2012
    Publication date: October 30, 2014
    Inventors: Stephen Dewhurst, David Easterhoff, Brad Nilsson, John Dimaio, Alan Smrcka, Jerry Yang, Christina Capule
  • Publication number: 20140315843
    Abstract: The present invention relates to a topical pharmaceutical composition of thiocolchicoside and methylsulfonylmethane comprising at least one penetration enhancer and one or more gelling agent. Furthermore, the invention relates to process for preparing the said topical pharmaceutical composition and its use for the treatment of pain and inflammatory symptoms associated with muscle-skeletal system and osteoarthritis.
    Type: Application
    Filed: December 14, 2012
    Publication date: October 23, 2014
    Inventors: Umit Cifter, Ali Turkyilmaz, Nur Pehlivan Akalin, Ramazan Onder
  • Publication number: 20140308374
    Abstract: The present invention describes a formulation comprising a prune and/or plum concentrate, and one or more water-soluble, non-digestible, prebiotic oligosaccharides. Optionally, one or more low calorie sweeteners, an antioxidant, calcium sennosides, or sennosides extract, PEG-3350, licorice, cocoa, coffee, tea flavors; fruit flavorings and spice flavorings, gelatin, agar-agar, carrageenan, pectin or cocoa powder are added. Other ingredients may be present as dietary supplements such as water-soluble vitamins, lipid-soluble vitamins; amino acids, maltodextrin, resveratrol, caffeine, mineral supplements, or natural sleep aids for use as a laxative, A variety of formulations are possible, such as premix, a laxative+energy power drink or power bar, or as a prebiotic supplement in probiotic yogurts, or in the form of gummies, chocolates, candies, and desserts such as red beans Japanese desserts.
    Type: Application
    Filed: November 2, 2012
    Publication date: October 16, 2014
    Applicant: Jiva Pharma, Inc.
    Inventor: Om P Goel
  • Publication number: 20140308348
    Abstract: This invention is a novel pharmaceutical composition comprising flurbiprofen or a pharmaceutically acceptable salt thereof in combination with an ?-2 adrenergic receptor agonist or a gamma-aminobutiric acid receptor agonist with anti-inflammatory, analgesic and myorelaxant activity.
    Type: Application
    Filed: May 20, 2014
    Publication date: October 16, 2014
    Applicant: Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi
    Inventors: Umit Cifter, Ali Turkyilmaz, Hasan Ali Turp
  • Patent number: 8853174
    Abstract: An agent for preventing or ameliorating skin aging, which exhibits a more excellent effect on the suppression of formation, or the amelioration, of wrinkles on the skin or sagging skin. An agent for preventing or ameliorating skin aging, containing triterpenoid saponins represented by the following formula (1) as an active ingredient, wherein at least one of R1 and R2 is a tigloyl group and the other represents a tigloyl group or an angeloyl group; R3 represents a methyl group or a hydroxymethyl group; and R4 represents Glc, Xyl or Gal.
    Type: Grant
    Filed: February 26, 2009
    Date of Patent: October 7, 2014
    Assignee: Kao Corporation
    Inventors: Akiyo Kameyama, Tsutomu Fujimura
  • Patent number: 8841265
    Abstract: This invention provides a composition comprising a triterpenoid saponin, comprising two side groups attached to carbons 21, and 22 of the triterpenoid saponin backbone, for inhibiting skin or ovarian tumor cell growth.
    Type: Grant
    Filed: December 29, 2008
    Date of Patent: September 23, 2014
    Assignee: Pacific Arrow Limited
    Inventors: Pui-Kwong Chan, May Sung Mak, Yun Wang
  • Patent number: 8828955
    Abstract: The invention aims at finding a highly-safe natural product having glutathione production-enhancing activity, and providing a glutathione production enhancer and a prophylactic/therapeutic agent for diseases caused by glutathione deficiency using that natural product as an active ingredient. The glutathione production enhancer or the prophylactic/therapeutic agent for diseases caused by glutathione deficiency contains, as an active ingredient, a licorice extract composition that contains liquiritin, liquiritigenin, isoliquiritin and isoliquiritigenin but contains substantially no glycyrrhizic acid.
    Type: Grant
    Filed: May 1, 2009
    Date of Patent: September 9, 2014
    Assignee: Maruzen Pharmaceuticals Co., Ltd.
    Inventors: Nobuaki Ohto, Toshiyuki Murakami, Hirokazu Ohno
  • Publication number: 20140227260
    Abstract: The present invention relates to new aminopyrimidine inhibitors of tyrosine kinase activity, pharmaceutical compositions thereof, and methods of use thereof.
    Type: Application
    Filed: April 21, 2014
    Publication date: August 14, 2014
    Applicant: Auspex Pharmaceuticals, Inc.
    Inventor: Chengzhi Zhang
  • Patent number: 8796233
    Abstract: Provided herein are bitter taste receptor ligands, related agents, combinations, compositions, methods and systems for modulating release of a metabolic hormone in vitro or in vivo from cells of the GI tract of an individual.
    Type: Grant
    Filed: June 17, 2011
    Date of Patent: August 5, 2014
    Assignees: California Institute of Technology, The Regents of the University of California, The United States of America as represented by the Department of Veterans Affairs
    Inventors: William A. Goddard, III, Mark Menna, Stephen Pandol, Ravinder Abrol
  • Patent number: 8785405
    Abstract: This invention provides a method of synthesizing new active compounds for pharmaceutical uses including cancer treatment, wherein the cancers comprise breast, leukocytic, liver, ovarian, bladder, prostatic, skin, bone, brain, leukemia, lung, colon, CNS, melanoma, renal, cervical, esophageal, testicular, spleenic, kidney, lymphatic, pancreatic, stomach and thyroid cancers. This invention is an anti adhesion therapy which uses the compound as a mediator or inhibitor of adhesion proteins and angiopoietins. It inhibits excess adhesion and inhibits cell attachment. It modulates angiogenesis. The compounds also use as mediator of cell adhesion receptor, cell circulating, cell moving and inflammatory diseases.
    Type: Grant
    Filed: September 6, 2013
    Date of Patent: July 22, 2014
    Assignee: Pacific Arrow Limited
    Inventors: Pui-Kwong Chan, May Sung Mak
  • Patent number: 8772253
    Abstract: Aureolic acid derivatives, process for obtaining them and uses thereof. This invention provides a bacterial strain that produces compound belonging to the family of aureolic acids useful in the treatment of cancer or nervous system diseases.
    Type: Grant
    Filed: July 14, 2010
    Date of Patent: July 8, 2014
    Assignee: Entrechem, S.L.
    Inventors: Luz Elena Núñez González, Nuria Menéndez Sánchez, Javier González Sabin, Francisco Moris Varas, Beatriz García Fernández, Maria Pérez Solares, Alfredo Fernández Braña, Maria del Carmen Méndez Fernández, José Antonio Salas Fernández
  • Publication number: 20140179624
    Abstract: Disclosed herein are novel cytoprotective derivatives of avicin D, including those of the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising these derivative compounds. Methods and intermediates useful for making the derivatives, and methods of using the derivatives and compositions thereof, including for the treatment of cancer, are also provided.
    Type: Application
    Filed: December 20, 2013
    Publication date: June 26, 2014
    Applicant: Research Development Foundation
    Inventors: Jordan GUTTERMAN, Valsala HARIDAS, Peter C. MICHELS, Yuri L. KHMELNITSKY, Vadim M. MOZHAEV
  • Patent number: 8748401
    Abstract: The present invention provides hydroxyl, keto, and glucuronide derivatives of 3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile.
    Type: Grant
    Filed: June 13, 2013
    Date of Patent: June 10, 2014
    Assignee: Incyte Corporation
    Inventors: James D. Rodgers, Adam Shilling, Argyrios G. Arvanitis, Stacey Shepard, Laurine G. Galya, Mei Li, Frank M. Nedza
  • Publication number: 20140154180
    Abstract: This invention relates, e.g., to a method for designing or selecting on a computer a candidate small molecule amyloid binder or inhibitor, comprising: a) docking test compounds to the binding site or binding surface determined from the three-dimensional structure of a co-crystal of a protofilament of an amyloid protein bound to a small molecule which is known to bind to the amyloid protein, and (b) selecting test compounds which exhibit an energy below that of the small molecule used to form the co-crystal made in a), as candidate amyloid binders.
    Type: Application
    Filed: July 16, 2012
    Publication date: June 5, 2014
    Applicant: The Regents of the University of California
    Inventors: David S. Eisenberg, Lin Jiang, Meytal Landau, Cong Liu
  • Publication number: 20140155342
    Abstract: The present invention relates to a patch for the transdermal release of diclofenac or a pharmaceutically acceptable salt thereof, in particular diethylamine salt, and thiocolchicoside.
    Type: Application
    Filed: June 15, 2012
    Publication date: June 5, 2014
    Applicant: EPIFARMA SRL
    Inventor: Giuseppe Irianni
  • Patent number: 8735558
    Abstract: This invention provides methods, processes, compounds and compositions for modulating the gene expression and modulating the secretion, expression, or synthesis of adhesion proteins or their receptors to cure disease, wherein the modulating comprises positive and negative regulating; wherein comprises inhibiting cancer growth, wherein the adhesion proteins or receptors comprise fibronectin, integrins family, Myosin, vitronectin, collagen, laminin, Glycosylation cell surface proteins, polyglycans, cadherin, heparin, tenascin, CD 54, CAM, elastin and FAK; wherein the methods, processes, compounds and compositions are also for anti-angiogenesis; wherein the cancers comprise breast cancer, leukocyte cancer, liver cancer, ovarian cancer, bladder cancer, prostate cancer, skin cancer, bone cancer, brain cancer, leukemia cancer, lung cancer, colon cancer, CNS cancer, melanoma cancer, renal cancer or cervix cancer.
    Type: Grant
    Filed: August 14, 2009
    Date of Patent: May 27, 2014
    Assignee: Pacific Arrow Limited
    Inventors: Pui-Kwong Chan, May Sung Mak
  • Patent number: 8734821
    Abstract: A silicone surfactant-based synergistic agricultural formulation contains a combination of a first defined silicone surfactant and a second defined silicone surfactant in a concentration sufficient to cause a knockdown level on treated arthropods, even in the absence of known pesticidally active ingredients.
    Type: Grant
    Filed: May 10, 2007
    Date of Patent: May 27, 2014
    Assignee: OMS Investments, Inc.
    Inventors: Shannon Hollis, Jason Rader, Casey McDonald
  • Patent number: 8729034
    Abstract: Acaciaside-B (Ac-B) has emerged as a prospective candidate molecule for prevention of HIV infection along with potential for use as/in vaginal contraceptive/formulation. It possesses anti-HIV property at a tolerably low concentration, is non-mutagenic and does not harm the niche of Lactobacilli. Thus Ac-B appears to be a superior ingredient for formulations of a chemical barrier against HIV-1 infection wherein its spermicidal property is superfluous.
    Type: Grant
    Filed: May 27, 2008
    Date of Patent: May 20, 2014
    Assignee: Council of Scientific and Industrial Research
    Inventors: Syed Nazrul Kabir, Heramba Nanda Ray, Bikash C. Pal, Debashis Mitra
  • Patent number: 8716346
    Abstract: This application provides compositions and methods useful in the treatment of certain cancers. In part, this application is based on the recognition that certain molecules that target abasic lesions or AP sites in DNA improve, augment, or potentiate the chemotherapeutic efficacy of certain anticancer agents.
    Type: Grant
    Filed: July 22, 2011
    Date of Patent: May 6, 2014
    Assignee: Case Western Reserve University
    Inventors: Stanton Gerson, Lili Liu
  • Publication number: 20140121177
    Abstract: A soy saponin composition is provided high bodily absorption characteristics. In an embodiment, a soyasapogenol composition comprises soyasapogenol B and 3-O-D-glucuronopyranosyl soyasapogenol B. The weight ratio (B/A) of the 3-O-D-glucuronopyranosyl soyasapogenol B to the soyasapogenol B is in the range of 0.001-10. The composition can be produced by partial decomposition of a sugar chain residue of a soy saponin B group glycoside utilizing an acid.
    Type: Application
    Filed: December 20, 2013
    Publication date: May 1, 2014
    Applicant: J-OIL MILLS, INC.
    Inventors: Shuichi KAMO, Toshiro SATO, Shunsuke SUZUKI
  • Publication number: 20140121176
    Abstract: Wash compositions for topical application are described. The compositions can be stable and well tolerated. Also described, are methods of using such compositions as cosmetic or pharmaceutical products. For example, the compositions can be used for cleansing the skin, preferably of acne patients, without compromising the skin barrier or resulting in over-compensation of sebum production. A topical wash composition is also described that can include: a) at least one surfactant; b) a zinc salt of gluconic acid; and c) a salt or derivative of glycyrrhizic acid or of glycyrrhetinic acid.
    Type: Application
    Filed: May 29, 2012
    Publication date: May 1, 2014
    Applicant: Galderma S.A.
    Inventor: Karine Nadau Fourcade
  • Patent number: 8691778
    Abstract: A topical pharmaceutical gel includes flurbiprofen or a pharmaceutically acceptable salt of flurbiprofen, thiocolchicoside or a pharmaceutically acceptable salt of thiocolchicoside, and menthol. Pharmaceutical combinations of flurbiprofen, thiocolchicoside, and menthol in the form of topical gels with anti-inflammatory, analgesic, and myorelaxant activities are described.
    Type: Grant
    Filed: September 20, 2010
    Date of Patent: April 8, 2014
    Assignee: Sanovel Ilac Sanayi ve Ticaret Anonim Sirketi
    Inventors: Fatih Cakir, Ali Turkyilmaz, Umit Cifter
  • Publication number: 20140088030
    Abstract: The invention relates to the preparation of phenolics derivatives by enzymatic condensation of phenolics selected among pyrocatechol or its derivatives with the glucose moiety of sucrose. The production of said phenolics derivatives is achieved with a glucosyltransferase (EC 2.4.1.5). These O-?-glucosides of selected phenolics are new, have a solubility in water higher than that of their parent polyphenol and have useful applications in cosmetic and pharmaceutical compositions, such as antioxidative, antiviral, antibacterial, immune-stimulating, antiallergic, antihypertensive, antiischemic, antiarrythmic, antithrombotic, hypocholesterolemic, antilipoperoxidant, hepatoprotective, anti-inflammatory, anticarcinogenic, antimutagenic, antineoplastic, anti-thrombotic and vasodilatory formulations, or in any other field of application.
    Type: Application
    Filed: November 20, 2013
    Publication date: March 27, 2014
    Inventors: DANIEL AURIOL, RENAUD NALIN, PATRICK ROBE, FABRICE LEFEVRE
  • Patent number: 8680061
    Abstract: A method for producing a pharmaceutical composition comprising a combination of phospholipid and glycyrrhizic acid or a pharmaceutically acceptable salt thereof, which composition is hydratable to produce an injectable medicinal form, said method comprising subjecting a mixture of phospholipid and an aqueous solution of glycyrrhizic acid or a pharmaceutically acceptable salt thereof and a carbohydrate to homogenization, for example at 800-1200 bar pressure at a temperature of less than 90° C., and subjecting the product of the homogenization to a sublimation drying step to produce said composition. Compositions obtainable using this method, and hydrated forms of these ready for administration by injection form further aspects of the invention.
    Type: Grant
    Filed: August 11, 2006
    Date of Patent: March 25, 2014
    Inventors: Alexandr Ivanovich Archakov, Mariya Kirillovna Guseva, Vasiliy Fedorovich Uchaikin, Elena Georgievna Tikhonova, Olga Mikhailovna Ipatova
  • Publication number: 20140080780
    Abstract: Herein, methods of modulating inclusion formation and stress granules in cells are described. The methods comprise contacting a cell with an inclusion inhibitor. Methods for screening for modulators of TDP-43 aggregation are also described.
    Type: Application
    Filed: May 21, 2012
    Publication date: March 20, 2014
    Inventor: Benjamin WOLOZIN
  • Publication number: 20140073592
    Abstract: Codling moth, Cydia pomonella, (L.), is a cosmopolitan pest of the apple, potentially causing damage to circa 80% of the fruit. Disclosed here are use of extract of Ginkgo biloba, or its synthetic metabolites for preventing or treating apple feeding and infestation by neonate larvae of codling moth.
    Type: Application
    Filed: September 11, 2013
    Publication date: March 13, 2014
    Applicant: Missouri State University
    Inventors: Maciej A. Pszczolkowski, Kevin Durden, Samantha Sellars, Brian Cowell, John J. Brown
  • Publication number: 20140072663
    Abstract: A method is provided for treating an individual for a malarial infection, in particular drug-resistant species of Plasmodium, including administering to the individual in need of such treatment a composition comprising an extract containing an effective amount of one or more anti-malarial di- or tri-terpene compounds. Potent and effective extracts containing the anti-malarial compounds can be derived from Luo Han fruit and Stevia leaves, including combinations of the same, for the purpose of treating and preventing malaria in an inexpensive manner from readily available commodities. In one embodiment, the composition is administered orally in a solid or liquid ingestible form.
    Type: Application
    Filed: September 10, 2011
    Publication date: March 13, 2014
    Applicant: FEBRIS BIO-TECH LIMITED
    Inventors: Garth Selwyn Smith, Lixin Zhang, Huanqin Dai
  • Publication number: 20130345160
    Abstract: To provide a glycyrrhizin/aminoacetic acid/cysteine combination drug containing an active ingredient in high concentration and excelling in stability and safety. Stability at compounding of active ingredient in high concentration has been improved by avoiding the addition of sulfite salts having been used as a stabilizer in existing products. As glycyrrhizin high-concentration preparations, there is provided a drug composition comprising 8 to 16 mg/mL of glycyrrhizin, 3 to 6 mg/mL of cysteine and 80 to 160 mg/mL of aminoacetic acid wherein no sulfite salts are added as an additive, and pH is 6 to 7.
    Type: Application
    Filed: August 26, 2013
    Publication date: December 26, 2013
    Applicant: NIPPON ZOKI PHARMACEUTICAL CO., LTD.
    Inventors: Taro YOSHIKAWA, Satoshi HANAOKA
  • Publication number: 20130345146
    Abstract: Systems and methods are disclosed herein for applying near-infrared optical energies and dosimetries to alter the bioenergetic steady-state trans-membrane and mitochondrial potentials (??-steady) of all irradiated cells through an optical depolarization effect. This depolarization causes a concomitant decrease in the absolute value of the trans-membrane potentials ?? of the irradiated mitochondrial and plasma membranes. Many cellular anabolic reactions and drug-resistance mechanisms can be rendered less functional and/or mitigated by a decrease in a membrane potential ??, the affiliated weakening of the proton motive force ?p, and the associated lowered phosphorylation potential ?Gp. Within the area of irradiation exposure, the decrease in membrane potentials ?? will occur in bacterial, fungal and mammalian cells in unison. This membrane depolarization provides the ability to potentiate antimicrobial, antifungal and/or antineoplastic drugs against only targeted undesirable cells.
    Type: Application
    Filed: August 12, 2013
    Publication date: December 26, 2013
    Applicant: NOMIR MEDICAL TECHNOLOGIES, INC.
    Inventor: Eric Bornstein
  • Publication number: 20130345159
    Abstract: A cardiogenin major isomer is obtained from a methanol extract of Geum japonicum and separated from its minor isomer. The separation of the two isomers can be achieved by chiral phase chromatography, e.g., using a Chiralpak® IC™ column. The purity of the isolated cardiogenin major isomer can be further increased by crystallization, yielding isolated cardiogenin major isomer having HPLC purity as high as 98.97% (a/a) at 210 nm and a potency of 95.50%) (w/w).
    Type: Application
    Filed: December 21, 2011
    Publication date: December 26, 2013
    Applicant: HUYA BIOSCIENCE INTERNATIONAL LLC
    Inventors: Andreas Kyas, Ernst Freund, Oliver Schlörke, Joerg Lill, Lars Rogall, Dario Menia, Gary Elliott, James Paterniti
  • Patent number: 8614197
    Abstract: This invention provides a method for treating cancer by blocking the migration, metastasis of cancer cells, growth of cancers wherein the cancers comprise breast cancer, leukocyte cancer, liver cancer, ovarian cancer, bladder cancer, prostate cancer, skin cancer, bone cancer, brain cancer, leukemia cancer, lung cancer, colon cancer, CNS cancer, melanoma cancer, renal cancer or cervix cancer. This invention provides uses of compositions comprising a triterpenoidal saponin, triterpenoid, triterpenoidal compound or sapongenin, comprising at least two side groups selected from the group consisting of angeloyl groups, tigloyl groups and senecioyl groups, wherein the side groups are attached to carbon 21, 22 or/and 28 of triterpenoidal sapogenin, triterpenoid, triterpenoidal compound or other sapongenin backbones.
    Type: Grant
    Filed: March 7, 2007
    Date of Patent: December 24, 2013
    Assignee: Pacific Arrow Limited
    Inventors: Pui-Kwong Chan, May Sung Mak, Yun Wang
  • Publication number: 20130338089
    Abstract: This invention provides methods, processes, compounds and compositions for modulating the gene expression or secretion of adhesion proteins, angiopoietins or their receptors to cure diseases, for anti-angiogenesis and for treating parasites, wherein the adhesion proteins or receptors comprise fibronectin, integrins family, myosin, vitronectin, collagen, laminin, glycosylation cell surface proteins, polyglycans, cadherin, heparin, tenascin, CD 54, CAM, elastin and FAK; wherein the angiopoietins comprise angiopoietin 1, angiopoietin 2, angiopoietin 3, angiopoietin 4, angiopoietin 5, angiopoietin 6, angiopoietin 7, angiopoietin-like 1, angiopoietin-like 2, angiopoietin-like 3, angiopoietin-like 4, angiopoietin-like 5, angiopoietin-like 6, and angiopoietin-like 7; wherein the cancers comprise breast cancer, leukocyte cancer, liver cancer, ovarian cancer, bladder cancer, prostate cancer, skin cancer, bone cancer, brain cancer, leukemia cancer, lung cancer, colon cancer, CNS cancer, melanoma cancer, renal cancer, c
    Type: Application
    Filed: March 15, 2013
    Publication date: December 19, 2013
    Inventors: Pui-Kwong CHAN, May Sung MAK, Yun WANG